Nasdaq

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...
Nasdaq

Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

“We are implementing a strategic realignment of Lexicon around some truly compelling assets, with a focus on LX9211 for neuropathic pain and other early-stage research and development programs,” said ...
Seeking Alpha

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development ...
GEN

Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration

Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...
Business Insider

Lexicon Announces Proposed Public Offering of Common Stock

THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon ”) today announced that it has commenced an underwritten public offering to offer and ...
American Association of Individual Investors

Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 7.18%

As of Tuesday, February 24, Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 7.18%, which has investors ...
Houston Chronicle

(PRN) Lexicon Pharmaceuticals Announces Two Agreements to Finance Long-Term Drug Development Strategy

INVUS TO INVEST $205 MILLION IN COMMON STOCK AT SIGNIFICANT PREMIUM SYMPHONY TO FUND ADDITIONAL $60 MILLION TO ADVANCE FIRST THREE DRUGS THE WOODLANDS, Texas, June 17 ...